Pharmaceutical contract manufacturing contributes significantly to the overall outsourcing market, due to its acceptance and widespread implementation by pharmaceutical companies. Cost reduction concerns originating from global economic constraints, has implied enormous pressure on pharmaceutical manufacturers to contain the cost of end-products. Pharmaceutical contract manufacturing divides production of goods by outside firms, under the brand of another firm, providing service to several manufacturers based on customized designs or specifications. Previously, pharmaceutical industry required companies to be vertically cohesive, i.e., the company itself conducted all operations required in production, however, currently investors require continued high fiscal performance, and as a result outsourcing has become a significant way of conducting business.
The global pharmaceutical market is going through critical change because of factors such as the need for reducing costs and minimizing product development rate, without conceding efficiency or production proficiency, decline in R&D activity, reduction in patent tenure, and growing innovative drugs are demanding pharmaceutical and bio-technology companies to drag drug prices. However, due to the economic slow-down in European countries, major pharma and biotechnology companies are ready to drop down their spending, resulting in increased contract manufacturers, globally.
Merger and acquisition activity has been widespread among both benefactor companies and contract manufacturers, leading to amalgamation among both sectors. Several pharmaceutical companies have acquired contract manufacturers to attain vertical integration. Other companies have adopted investment in their own manufacturing capabilities by developing concise, adaptable, multi-product facilities designated to meet the changing needs of pharmaceutical market. Both strategies are appointed to restrict the demand for outsourcing. Hence, contract service providers that demand growth going forward are expected to provide added-value to finished products for attracting pharmaceutical contractors. Emerging economies, super generics, and bio-similar products provide other latent prospects for growth with contract manufacturers attaining global reach and technical capabilities required to exploit them.
The global pharmaceutical contract manufacturing market is segmented by type of contract manufacturing and regions. By type of contract manufacturing, the pharmaceutical contract manufacturing market is segmented into advanced drug delivery products, final dosage form (FDF), active pharmaceutical ingredients (API)/bulk drug, packaging contract manufacturing and OTC medicines and nutritional products. The final dosage form (FDF) of contract manufacturing is estimated to develop with substantial rate due to increasing need for generic drug products and rising R&D activities. Geographically, world pharmaceutical contract manufacturing market is divided into North America, Europe, Asia-Pacific and Latin America and Middle East and Africa. The demand in Asia-Pacific is analyzed to be the major driving factor for the growth of the global pharmaceutical contract manufacturing market. China is analyzed to lead the demand for pharmaceutical contract manufacturing due to increased industrial production in the last 3–4 years. It is the leading consumer of pharmaceutical contract manufacturing in the world. The markets in other emerging economies such as Brazil and India are also projected to grow rapidly.
Key players involved in the global pharmaceutical contract manufacturing market are focusing on key market strategies including mergers and acquisitions with local as well as established players. Moreover, companies are also focusing on collaborating with local players to increase their reach across all geographies and earn huge profits. Partnership with multinational companies to strengthen their market reach and goodwill is also anticipated to be a major market strategy in the global pharmaceutical contract manufacturing market. Some of the major players involved in the manufacture and supply of pharmaceutical contract manufacturing include Aenova, Fareva, Catalent, Lonza, Amgen, Gedeon Richter, Apotex, AstraZeneca, Baxter, Cipla, Biocon Boehringer Ingelheim, Pfizer CentreOne, Celltrion, Coherus Biosciences, Berlin-Chemie, Daiichi Sankyo, Abbott, Dr. Reddy's Laboratories, , Biogen, Eli Lilly, Emcure Pharmaceuticals, Aspen, Eurofarma Laboratories, Gilead Sciences, Aurobindo Pharma, and GlaxoSmithKline (GSK).
Market by Type
· Advanced drug delivery products
· Final dosage form (FDF)
· Active pharmaceutical ingredients (API)/bulk drug
· Packaging contract manufacturing
· OTC medicines and nutritional products
Market by Geography
· North America
o Rest of Europe
o Rest of Asia-Pacific
· Latin America
o Rest of Latin America
· Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o Rest of MEA
The global medical nonwoven disposables market is forecasted to grow at a CAGR of 6.6% over the forecast time frame and reach around US$ 26.1 billion by 2026. The report provides analysis of global medical non-woven disposables market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year. Market Insights Nonwovens are a unique category of textile product enginee
According to Acumen Research and Consulting, the global plastic surgery instruments market size is anticipated to reach around US$ 1.7 billion by 2026 and expected to grow at a CAGR of 8.5% from period 2019 to 2026. Plastic surgery involves the restoration, replacement, alteration and rehabilitation of body regions, such as the head, skin, musculoskeletal, breast and others. The two main kinds of plastic surgery are cosmetic and reconstructive. Cosmetic o
According to Acumen Research and Consulting, the global upper limb prosthetics market size is expected to worth US$ 1.9 billion by 2026 and poised to grow at a CAGR around 10.5 % from period 2019 to 2026. The prothetics of the upper limbs have gone a long way from their ancient origins to advanced and advanced protheses of today's moments. Today, the highest prothesis implants consist of aluminum, plastics and sophisticated composite components. The
According to Acumen Research and Consulting, the global MRI-guided neurosurgical ablation market is forecasted to grow at a CAGR around 4.3% from period 2019 to 2026 and reach around US$ 5.4 billion by 2026. The report provides analysis of global MRI-guided Neurosurgical Ablation market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year. Market Insights An gr
Introduction According to Acumen Research and Consulting, The global self-monitoring blood glucose devices market size is expected to reach US$ 19 billion by 2026 and market is growing at a CAGR of 5 % from 2019 to 2026. Diabetes is a clinical disorder in which the blood glucose level rises owing to the pancreas ' incapacity to generate insulin. Monitoring glucose is one of the most important measures in the leadership of diabetes
Introduction According to Acumen Research and Consulting, the global ovarian cancer diagnostics market is forecasted to grow at striking CAGR around 5.9 % over the forecast time frame and reach around US$ 1.8 billion by 2026. One of the most prevalent kinds of cancer in females is ovarian cancer. It is a cancer which begins in the ovaries. Ovary is a woman reproductive organ that contains eggs or ova. There are two ovaries i